UBS raised the firm’s price target on Align Technology to $280 from $260 and keeps a Neutral rating on the shares. Sentiment on Align’s Q4 results was mixed amid soft December orthodontia volumes data in the U.S., with poor weather and contributing to more acute concern around the Q1 outlook, but the better Q1 revenue outlook and full year guidance that matched subdued consensus revenues estimates and y/y margin improvement suggests better management visibility than over the past year, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALGN:
- Options Volatility and Implied Earnings Moves Today, January 31, 2024
- ALGN Earnings this Week: How Will it Perform?
- Align Technology price target raised to $285 from $250 at Stifel
- Align Technology put volume heavy and directionally bearish
- Align receives FDA 510(k) clearance for Invisalign Palatal Expander System
